keyword
MENU ▼
Read by QxMD icon Read
search

rheumatoid arthritis remission

keyword
https://www.readbyqxmd.com/read/28917375/total-glucosides-of-paeony-for-rheumatoid-arthritis-a-systematic-review-of-randomized-controlled-trials
#1
REVIEW
Jing Luo, Di-Er Jin, Guo-Yan Yang, Ying-Ze Zhang, Jian-Ming Wang, Wei-Ping Kong, Qing-Wen Tao
BACKGROUND: Total glucosides of paeony (TGP) is commonly used to treat rheumatoid arthritis (RA) in China. However, clinical practice hasn't been well informed by evidence from appropriately conducted systematic reviews. This PRISMA-compliant systematic review aims at examining the effectiveness and safety of TGP for RA. METHODS: Randomized controlled trials (RCTs) comparing TGP with placebo, no treatment, or disease-modifying antirheumatic drugs (DMARDs) for patients with RA were retrieved by searching seven databases...
October 2017: Complementary Therapies in Medicine
https://www.readbyqxmd.com/read/28914855/-late-onset-rheumatoid-arthritis-in-a-patient-with-successfully-treated-iga-nephropathy
#2
N V Chebotareva, I N Bobkova, S V Gulyaev
The paper describes a rare clinical case of rheumatoid arthritis (RA) that developed in a patient 9 years after diagnosing IgA nephropathy. Kidney disease was characterized by a stable course with moderate urinary syndrome, hypertension, and reduced renal function. Immunosuppressive therapy using glucocorticosteroids and then mycophenolic acid led to remission of nephritis and recovery of renal function. However, the absence of nephritis activity and discontinuation of immunosuppressants was responsible for articular syndrome...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28893220/the-added-value-of-musculoskeletal-ultrasound-to-clinical-evaluation-in-the-treatment-decision-of-rheumatoid-arthritis-outpatients-physician-experience-matters
#3
C Sifuentes-Cantú, I Contreras-Yáñez, L Saldarriaga, A C Lozada, M Gutiérrez, V Pascual-Ramos
BACKGROUND: Musculoskeletal ultrasound improves the accuracy of detecting the level of disease activity (DA) in RA patients, although its impact on the final treatment decision in a real clinical setting is uncertain. The objectives were to define the percentage of clinical scenarios from an ongoing cohort of RA outpatients in which the German Ultrasound Score on 7 joints (GUS-7) impacted the treatment and to explore if the impact differed between a senior rheumatologist (SR) vs. a trainee (TR)...
September 11, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28884785/certolizumab-pegol-cdp870-for-rheumatoid-arthritis-in-adults
#4
REVIEW
Vicente Ruiz Garcia, Amanda Burls, Juan B Cabello, Paloma Vela Casasempere, Sylvia Bort-Marti, José A Bernal
BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) for reducing the risk of joint damage, improving physical function and improving the quality of life. This review is an update of the 2014 Cochrane Review of the treatment of RA with certolizumab pegol. OBJECTIVES: To assess the clinical benefits and harms of certolizumab pegol (CZP) in people with RA who have not responded well to conventional disease-modifying anti-rheumatic drugs (DMARDs)...
September 8, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28883856/interleukin-21-gene-polymorphism-rs2221903-is-associated-with-disease-activity-in-patients-with-rheumatoid-arthritis
#5
Damian Malinowski, Agnieszka Paradowska-Gorycka, Krzysztof Safranow, Andrzej Pawlik
INTRODUCTION: Interleukin-21 (IL-21) is a cytokine which plays a significant role in the pathogenesis and disease activity of rheumatoid arthritis (RA). Genetic polymorphisms in the IL-21 gene may alter the synthesis of IL-21. The aim of this study was to examine IL-21 and IL-21R polymorphisms in patients with RA. MATERIAL AND METHODS: We examined 422 patients with RA and 338 healthy controls. Single nucleotide polymorphisms (SNPs) within the IL-21 (rs6822844 G>T, rs6840978 C>T, rs2221903 T>C) and IL-21R (rs2285452 G>A) genes were genotyped using TaqMan genotyping assays...
August 2017: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/28880691/changes-in-serum-interleukin-6-levels-as-possible-predictor-of-efficacy-of-tocilizumab-treatment-in-rheumatoid-arthritis
#6
Motohiko Aizu, Ichiro Mizushima, Satoshi Nakazaki, Akikatsu Nakashima, Takashi Kato, Takashi Murayama, Shinichi Kato, Yasuo Katsuki, Kunihiro Ogane, Hiroshi Fujii, Kazunori Yamada, Hideki Nomura, Akihiro Yachie, Masakazu Yamagishi, Mitsuhiro Kawano
OBJECTIVES: We aimed to evaluate the association between the change in serum IL-6 during the clinical course of tocilizumab (TCZ) therapy and rheumatoid arthritis (RA) disease activity or occurrence of adverse events. METHODS: General laboratory data including serum IL-6 levels and physical findings were obtained every 4 weeks, and, in addition, at the time when any adverse events occurred. RESULTS: The proportion achieving Clinical Disease Activity Index (CDAI) remission at 52 weeks was significantly lower in 20 patients with serum IL-6 ≥ 30 pg/ml at 12 weeks than 24 patients with serum IL-6 < 30 pg/ml...
September 7, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28879053/efficacy-of-embedded-nurse-led-versus-conventional-physician-led-follow-up-in-rheumatoid-arthritis-a-systematic-review-and-meta-analysis
#7
Annette de Thurah, Bente Appel Esbensen, Ida Kristiane Roelsgaard, Tove Faber Frandsen, Jette Primdahl
OBJECTIVE: To compare the efficacy of embedded nurse-led versus conventional physician-led follow-up on disease activity in patients with rheumatoid arthritis (RA). METHODS: In a systematic literature search, we identified randomised controlled trials (RCTs) reporting on the efficacy of nurse-led follow-up on disease control in patients with RA compared with physician-led follow-up. Primary outcome was disease activity indicated by Disease Activity Score (DAS)-28...
2017: RMD Open
https://www.readbyqxmd.com/read/28879052/obesity-is-a-strong-predictor-of-worse-clinical-outcomes-and-treatment-responses-in-early-rheumatoid-arthritis-results-from-the-swefot-trial
#8
Adrian Levitsky, Kerstin Brismar, Ingiäld Hafström, Karen Hambardzumyan, Cecilia Lourdudoss, Ronald F van Vollenhoven, Saedis Saevarsdottir
OBJECTIVES: The aim of this paper was to analyse the impact of obesity, in addition to known predictors, on disease outcome in early rheumatoid arthritis (RA). METHODS: Body mass index (BMI) was available in 260 patients from the Swedish pharmacotherapy trial (SWEFOT). Differences in disease activity (DAS28), functional impairment (HAQ), pain (Visual Analogue Scale, VAS-pain) and radiographic damage were evaluated over 24 months between BMI categories (obese BMI >30, n=43; overweight BMI=25-29...
2017: RMD Open
https://www.readbyqxmd.com/read/28875224/the-influence-of-fibromyalgia-on-achieving-remission-in-patients-with-long-standing-rheumatoid-arthritis
#9
Fausto Salaffi, Maria Chiara Gerardi, Fabiola Atzeni, Alberto Batticciotto, Rossella Talotta, Antonella Draghessi, Marco Di Carlo, Piercarlo Sarzi-Puttini
To investigate the influence of fibromyalgia (FM) on achieving remission defined on the basis of the Simplified Disease Activity Index (SDAI) remission criteria in patients with long-standing rheumatoid arthritis (RA). This observational longitudinal cohort consisted of long-standing RA patients being treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biological DMARDs (bDMARDs). After 6 months of follow-up, the patients fulfilling or not fulfilling the remission criteria were identified and compared with each other in terms of the presence of FM, neuropathic pain, and other comorbidities...
September 5, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28874419/early-intervention-in-crohn-s-disease-towards-disease-modification-trials
#10
REVIEW
Silvio Danese, Gionata Fiorino, Laurent Peyrin-Biroulet
Crohn's disease (CD) is a chronic progressive destructive inflammatory bowel disease. As in rheumatoid arthritis, there is increasing evidence that early treatment initiation with disease-modifying agents, such as biological drugs, may lead to complete disease control, prevention of disease progression thus protecting against irreversible damage and restoration of normal quality of life. Data from randomised clinical trials with immunosuppressants and biologics suggest that treating patients with a disease duration of <2 years and an absence of complications may significantly reduce the risk for complications and increase time in remission in patients with CD...
September 5, 2017: Gut
https://www.readbyqxmd.com/read/28870033/-the-expression-and-clinical-significance-of-proprotein-convertase-subtilisin-kexin-9-in-rheumatoid-arthritis
#11
Q Du, X J Yu, H J Li, S Q Guan, Z Y Zhang, Y F Mei
Objective: To assess the expression and significance of proprotein convertase subtilisin kexin 9 (PCSK9) in patients with rheumatoid arthritis (RA). Methods: Sixty-five RA patients and forty-seven healthy controls were recruited in this study. The body mass index (BMI) and serum total cholesterol(TC), triglyceride(TG), high density lipoprotein(HDL), lipoprotein a, low density lipoprotein(LDL), very low density lipoprotein(VLDL), apolipoprotein A(ApoA), apolipoprotein B(ApoB) and the ratio of LDL-C/HDL-C were tested...
September 1, 2017: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/28866645/optimal-methotrexate-dose-is-associated-with-better-clinical-outcomes-than-non-optimal-dose-in-daily-practice-results-from-the-espoir-early-arthritis-cohort
#12
Cécile Gaujoux-Viala, Nathalie Rincheval, Maxime Dougados, Bernard Combe, Bruno Fautrel
BACKGROUND: Although methotrexate (MTX) is the consensual first-line disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis (RA), substantial heterogeneity remains with its prescription and dosage, which are often not optimal. OBJECTIVE: To evaluate the symptomatic and structural impact of optimal MTX dose in patients with early RA in daily clinical practice over 2 years. METHODS: Patients included in the early arthritis ESPOIR cohort who fulfilled the ACR-EULAR (American College of Rheumatology/European League against Rheumatism) criteria for RA and received MTX as a first DMARD were assessed...
September 2, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28865423/patient-s-perspective-of-sustained-remission-in-rheumatoid-arthritis
#13
Irazú Contreras-Yáñez, Guillermo Guaracha-Basañez, Daniel Ruiz-Domínguez, Virginia Pascual-Ramos
BACKGROUND: During the course of rheumatoid arthritis (RA), patients have profound negative effects on their patient-reported-outcomes (PRO); in addition, the impact of sustained remission (SR) on PROs may differ for each particular outcome. The objectives of this study were to identify SR from an inception cohort of RA patients and to examine the impact of SR in an ample spectrum of PROs. METHODS: The study was developed in a well characterized and ongoing cohort of RA patients with recent onset disease recruited from 2004 onwards...
September 2, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28863153/triple-dmard-treatment-in-early-rheumatoid-arthritis-modulates-synovial-t-cell-activation-and-plasmablast-plasma-cell-differentiation-pathways
#14
Alice M Walsh, Mihir D Wechalekar, Yanxia Guo, Xuefeng Yin, Helen Weedon, Susanna M Proudman, Malcolm D Smith, Sunil Nagpal
OBJECTIVES: This study sought to investigate the genome-wide transcriptional effects of a combination of disease modifying anti-rheumatic drugs (tDMARD; methotrexate, sulfasalazine and hydroxychloroquine) in synovial tissues obtained from early rheumatoid arthritis (RA) patients. While combination DMARD strategies have been investigated for clinical efficacy, very little data exists on the potential molecular mechanism of action. We hypothesized that tDMARD would impact multiple biological pathways, but the specific pathways were unknown...
2017: PloS One
https://www.readbyqxmd.com/read/28861167/can-rheumatoid-arthritis-ever-cease-to-exist-a-review-of-various-therapeutic-modalities-to-maintain-drug-free-remission
#15
Di Liu, Na Yuan, Guimei Yu, Ge Song, Yan Chen
Therapies for rheumatoid arthritis (RA) were mostly aimed at reducing the pain, stiffness and further progression of joint destruction. However, with the advent of biologic agents that act against specific inflammatory cytokines contributing to RA pathogenesis (treat-to-target strategy), the degree of remission achieved has been remarkably impressive. In particular, inhibition of tumor necrosis factor α (TNFα), interleukins-1 and -6 and receptor-activator of nuclear kappa B ligand by neutralizing antibodies in early diagnosed RA patients has resulted in lowering of disease activity to levels that enable them to function as in the pre-disease stage...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28859326/similar-efficacy-and-safety-of-initial-cobra-light-and-cobra-therapy-in-rheumatoid-arthritis-4-year-results-from-the-cobra-light-trial
#16
Nicole P C Konijn, Lilian H D van Tuyl, Maarten Boers, Debby den Uyl, Marieke M Ter Wee, Lindsey K M van der Wijden, Irene E M Bultink, Pit J S M Kerstens, Alexandre E Voskuyl, Dirkjan van Schaardenburg, Michael T Nurmohamed, Willem F Lems
Objective: To assess the efficacy and safety of initial COBRA-light vs COBRA therapy in RA patients after a 4-year follow-up period. Methods: In the COBRA-light trial, 162 consecutive patients with recent-onset RA were randomized to either COBRA-light (prednisolone and MTX) or COBRA therapy (prednisolone, MTX and SSZ) for 1 year. After 1 year, treatment was continued without protocol, and adjusted by the treating physician according to clinical judgement, preferably with a treat-to-target strategy...
September 1, 2017: Rheumatology
https://www.readbyqxmd.com/read/28859325/drivers-of-patient-global-assessment-in-patients-with-rheumatoid-arthritis-who-are-close-to-remission-an-analysis-of-1588-patients
#17
Ricardo J O Ferreira, Maxime Dougados, John R Kirwan, Cátia Duarte, Maarten de Wit, Martin Soubrier, Bruno Fautrel, Tore K Kvien, José A P da Silva, Laure Gossec
Objectives: ACR/EULAR Boolean remission in RA is frequently not obtained solely due to a patient global assessment (PGA) >1/10 (a condition often designated as near-remission). This study aimed to assess which domains of impact could explain an elevated PGA in near-remission patients. Methods: We performed an ancillary analysis of data from three cross-sectional studies in patients with established RA. Three disease activity states were defined: remission (tender and swollen joint counts, CRP and PGA all ⩽1), near-remission (tender and swollen joint counts, and CRP are all ≤1 but PGA >1) and non-remission...
September 1, 2017: Rheumatology
https://www.readbyqxmd.com/read/28855692/rheumatoid-arthritis-remission-keeping-the-patient-experience-front-and-centre
#18
Lilian H D van Tuyl, Maarten Boers
No abstract text is available yet for this article.
August 31, 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28852832/down-titration-of-biologics-for-the-treatment-of-rheumatoid-arthritis-a-systematic-literature-review
#19
Chak Sing Lau, Allan Gibofsky, Nemanja Damjanov, Sadiq Lula, Lisa Marshall, Heather Jones, Paul Emery
Biologic therapies have improved the management of rheumatoid arthritis (RA) and the treat-to-target approach has resulted in many patients achieving remission. In the current treatment landscape, clinicians have begun considering dose reduction/tapering for their patients. Rheumatology guidelines in Asia, Europe, and the United States include down-titration of biologics but admit that the level of evidence is moderate. We conducted a systematic literature review to assess the published studies that evaluate down-titration of biologics in RA...
August 29, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28852410/management-of-chronic-spontaneous-urticaria-csu-a-treat-to-target-approach-using-a-patient-reported-outcome
#20
Hermenio Lima, Melinda Gooderham, Jan Dutz, Charles Lynde, Hugo Chapdelaine, Anne Ellis, Martin Gilbert, Vincent Ho, Kim Papp, Yves Poulin, Gordon Sussman
BACKGROUND: Treat-to-target therapy approaches are established for chronic diseases such as diabetes, hypertension, and more recently rheumatoid arthritis, resulting in improved patient outcomes. These approaches do not use patient reported outcomes (PRO) as targets of therapy. Chronic spontaneous urticaria (CSU), also called chronic idiopathic urticaria (CIU), is defined as recurrent urticaria of known and unknown cause, lasting more than 6 weeks. Treatment of CSU can be challenging...
2017: Allergy, Asthma, and Clinical Immunology
keyword
keyword
52663
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"